Analysts weighed in on biopharmaceutical stocks Horizon Pharma PLC (NASDAQ:
Horizon Pharma PLC
Dublin-based pharmaceutical company Horizon Pharma’s key drug, Actimmune, is aimed at treating Friedreich’s ataxia (FA), a degenerative neuro-muscular disorder. While the pharmaceutical company already has rights to Actimmune in the US, Canada, and Japan, Horizon just recently formed a new deal that may drive company success to new heights.
In light of recent progressions for Horizon, UBS analyst
Goodman noted, “Management is clearly excited about the FA indication, and it looks like it would like to lock up particularly Europe, a potentially large market for FA, and mgt believes it would get a better deal before the STEADFAST trial readouts.”
Further, the analyst explains that if FA works, the European market can surpass $200 million, which Goodman comments “would make the BI deal very...